See analyst estimates and all valuation multiples for Regenerative Medicine
| Company | EV | EV/LTM Revenue | EV/LTM EBITDA |
|---|---|---|---|
| $98.0B | 8.4x | 24.9x | |
| $10.5B | 3.4x | 12.3x | |
| $4.5B | 13.0x | 30.7x | |
| $3.6B | 10.3x | 28.4x | |
| $3.3B | 96.9x | -6.1x | |
| $2.6B | 4.4x | 36.9x | |
| $2.2B | 613.5x | -146.1x | |
| $1.7B | 6.6x | 26.5x | |
| $1.6B | 61.9x | -27.2x | |
| $1.5B | n/a | n/a | |
| $1.2B | 1540.6x | -49.3x | |
| $963M | 2.6x | 11.7x | |
| $867M | 14.5x | -1.9x | |
| $761M | 3.6x | 30.5x | |
| $717M | 1.5x | 16.8x | |
| $654M | 12.7x | -1.5x | |
| $623M | 21.7x | -3.9x | |
| $502M | n/a | n/a | |
| $445M | 14.5x | 30.1x | |
| $435M | 9.4x | 76.2x | |
| $366M | 310.4x | n/a | |
| $238M | 26.7x | -7.4x | |
| $216M | 85.6x | n/a | |
| $169M | 6.6x | 14.2x | |
| $168M | 18.7x | -2.0x | |
| $164M | 25.4x | -42.0x | |
| $158M | n/a | n/a | |
| $136M | 2.5x | 41.4x | |
| $130M | n/a | n/a | |
| $112M | 4.1x | -8.4x | |
| $104M | 0.9x | 16.4x | |
| $103M | 398.6x | -0.5x | |
| $91.3M | 0.4x | n/a | |
| $76.1M | n/a | n/a | |
| $71.8M | n/a | n/a | |
| $57.9M | n/a | n/a | |
| $51.1M | 585.2x | n/a | |
| $43.9M | 28.1x | n/a | |
| $28.8M | 9.4x | -4.1x | |
| $28.7M | n/a | n/a | |
| $28.0M | n/a | n/a | |
| $25.2M | 4.2x | n/a | |
| $20.2M | 81.5x | -0.1x | |
| $17.7M | n/a | n/a | |
| $7.9M | 4.9x | n/a | |
| -$105M | -1.2x | 0.7x |
Valuation multiples as of last 12 months (LTM). Financial data powered by Morningstar, Inc.
See analyst estimates and M&A multiples for Regenerative Medicine